OVERVIEW

A results-oriented networking event showcasing the latest innovations in technologies, services, and drugs in development. Drug Development & Delivery’s Innovation Networking Summit connects technology and services innovators/providers with R&D, preformulation, formulation development, business development, product life-cycle management, and corporate management professionals from the Pharmaceutical and Biotechnology industries.

^{*Use the promotional code “CADDI” to receive a 20% discount.}

AGENDA

• PART I:  Developing Better Treatments: Trends in Patient-Centric Drug Design 

Catalent Institute research suggests that a majority of recently approved drugs reflect design decisions likely to lead to sub-optimal real-world patient outcomes. Meanwhile, regulators and payors seek evidence that product designs are suitable for specific indications or patient populations, and physicians and patients continue to want less complex dosing regimens without compromising on treatment effectiveness.

During this section, we will present current thinking and trends in patient-centric design from three distinct perspectives, followed by group Q&A as time permits.

- NETWORKING BREAK -

• PART II:  Developing Better Treatments:  Predictive Design of Drug Products

Chris Lipinski’s 1997 Rule of Five has over the past 2 decades gained widespread popularity as a tool to evaluate whether a compound had the chemical properties to make it an orally active drug, thereby reducing the risk of attrition in clinical development. The criteria are an excellent starting paradigm, but more recent evidence suggests the Rule does not sufficiently address all of the pharmacokinetic and pharmacodynamic considerations. Today, newer in silico and in vitro technologies and approaches enable scientists to study and predict various pharmacokinetic and pharmacological properties of drugs, enabling them to optimize the drug molecule itself prior to first-in-man studies. In addition, more tools are also available to aid in the selection of the best formulation to deliver enhanced bioavailability. These evolving approaches will further minimize attrition risk in clinical stages, accelerate drug development, and likely yield resulting compounds with enhanced therapeutic profiles.

During this session, we will review the various tools available to design and optimize drugs, and discuss how an integrated approach can transform current drug development processes.

^{*Use the promotional code “CADDI” to receive a 20% discount.}

MEET THE SPEAKERS

Part I:  Developing Better Treatments: Trends in Patient-Centric Drug Design 

• “A Product Innovator’s Perspective” | Ronald Smith, PhD, Assistant Vice President, for Merck Research Labs
• “A Delivery Technology Innovator’s Perspective” | Cornell Stamoran, PhD, Vice President, Strategy for Catalent, Inc., & Co-Chair, Catalent Applied Drug Delivery Institute
• “A Clinical & Academic Perspective” | Rachel Meyers, PharmD, BCPS, BCPPS, Pediatric Pharmacist, St. Barnabas Medical Center, Clinical Associate Professor, Ernest Mario School of Pharmacy, Rutgers

Part II: Developing Better Treatments: Predictive Design of Drug Products

• “In Silico Tools for the Prediction of Drug Properties & Performance” | Ronak Savla, PharmD, PhD, Applied Drug Delivery Fellow, Catalent Applied Drug Delivery Institute
• “Optimization & Selection of Drug Formulation in the Preclinical Setting” | Stephen Tindal, BSc, Director, Science & Technology, Catalent Pharma Solutions